BioMarin to Present at the Citi Biotech Day

NOVATO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical
Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief
Executive Officer of BioMarin, will present a company update at the 3rd Annual
Citi Biotech Day in New York City on Monday, September 8, 2008 at 10:30 a.m.
ET.
Interested parties may access a live audio webcast of the conference call
via the investor section of the BioMarin website, http://www.BMRN.com. A
replay of the call will be archived on the site for one week following the
call.
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for
serious diseases and medical conditions. The company's product portfolio
comprises three approved products and multiple clinical and preclinical
product candidates. Approved products include Naglazyme(R) (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme(R) (laronidase) for
mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a
50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin
dihydrochloride) Tablets, a product for the treatment of phenylketonuria
(PKU), developed in partnership with Merck Serono, a division of Merck KGaA of
Darmstadt, Germany. Other product candidates include 6R-BH4 for
cardiovascular indications, which is currently in Phase 2 clinical development
for the treatment of peripheral arterial disease and sickle cell disease, and
PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is
currently in Phase 1 clinical development for the treatment of PKU. For
additional information, please visit http://www.BMRN.com. Information on
BioMarin's website is not incorporated by reference into this press release.
BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of
BioMarin Pharmaceutical Inc.
Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors Media
Eugenia Shen Susan Berg
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 506-6570 (415) 506-6594

SOURCE BioMarin Pharmaceutical Inc.

Investors, Eugenia Shen, +1-415-506-6570, or Media, Susan Berg,
+1-415-506-6594, both of BioMarin Pharmaceutical Inc.